Phillips-Medisize Wins Contract to Manufacture First Electronic-Enabled Combination Drug Delivery Product
- cts.businesswire.com
You can change your cookie consent to allow this kind of content permanently or click the button below to allow only the content in this release.
Phillips-Medisize, a Molex company, announced today an agreement with a leading biotechnology company to manufacture a wearable, electronic-enabled combination product. The product is a post-phase III development-stage combination drug and device that combines two-day, single use, disposable technology for subcutaneous drug delivery.
The wearable combination product – which is replaced every two days – is about the size of a hockey puck, and can either be adhered to the patient’s body, via an adhesive patch, or worn near the infusion site.
Phillips-Medisize, which built devices and supplied key data to support the FDA NDA submission, will provide final assembly, testing and quality control of this electronic combination product. Specifically, Phillips-Medisize will handle the prefilled drug cartridge that fits inside the device. This drug container is aseptically filled and shipped to Phillips-Medisize. Several state-of-the-art Phillips-Medisize facilities are involved in various stages of manufacturing the combination product – including molding, assembly, drug handling, labeling, reconciliation and more.
“This exciting new contract taps over 13 years of Phillips-Medisize’s combination product expertise, which includes cold chain drug handling and first programs with API handling. We have experience in manufacturing both combination and electronic-enabled drug delivery devices, and this is our first product submitted for FDA approval that includes both,” said Matt Jennings, CEO and President, Phillips-Medisize.
Pending receipt of FDA approval, Phillips-Medisize is contracted to provide commercialization services from its Hudson, WI-based manufacturing site. The combination product is slated for launch in 2H 2020. Backed by Phillips-Medisize’s scalability to move to high volume production, the product will be well positioned for a successful market launch.
Strong potential also exists to bring the device onto a connected health platform in the future, by embedding low-cost connectivity that will make it possible to capture and communicate data between patient and provider in order to help monitor adherence.
About Phillips-Medisize
Phillips-Medisize, a Molex company, is an end-to-end provider of innovation, development and manufacturing solutions to the pharmaceutical, diagnostics, medical device and specialty commercial market segments. Backed by the combined global resources of Molex and its parent company Koch Industries, Phillips-Medisize’s core advantage is the knowledge of its people to integrate design, molding, electronics, and automation, providing innovative, high-quality manufacturing solutions. For more information, please visit www.phillipsmedisize.com or www.molex.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191022005826/en/
Contact information
For more information, contact:
Heather Ditzler
Phone +1 715-377-7261
heather.ditzler@phillipsmedisize.com
Paula Kasper (Europe)
Phone +41448383933
paula.kasper@phillipsmedisize.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
StatLab Empowers Growth in Key European Countries through Direct Market Expansions in Germany and France13.8.2025 17:26:00 EEST | Press release
StatLab Medical Products (“StatLab”), a leading global developer and manufacturer of medical diagnostic supplies and equipment, today announced the completed acquisitions of Germany-based histology service and distribution company Histoserve GmbH (“Histoserve”) as well as Diapath France SAS (“Diapath France”). These moves mark a significant step forward in StatLab’s European growth strategy, expanding its direct commercial presence to the top four European markets: France, Germany, Italy, and the UK, a milestone that positions StatLab among the few suppliers with fully direct access to Europe’s largest pathology markets, enabling closer customer relationships and expanded access to StatLab’s full product portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250813235270/en/ Founded by Wolfgang Jakobi in 2010 near Hannover, Germany, Histoserve has evolved into a comprehensive solutions provider for pathology labs, providi
BM3EAC Corp. 2025 Semi-Annual Report13.8.2025 16:38:00 EEST | Press release
BM3EAC Corp. (the “Company”), a special purpose acquisition company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., today published its semi-annual report for the period 1 January 2025 to 30 June 2025. The semi-annual report can be downloaded from the Company’s website via the following link: https://www.BrigadeM3EAC.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER The Company’s semi-annual report referenced in this announcement may include forward-looking statements, which are based on the Company's current expectations and projections regarding a business combination, the business, the economy and other future conditions of the Company and speak only as of the date hereof. Forward-looking statements may
Andersen Consulting Expands Platform with Alamo Consultores13.8.2025 16:30:00 EEST | Press release
Andersen Consulting expands its technology transformation capabilities through a Collaboration Agreement with Alamo Consultores. Established in Argentina since 2012, Alamo Consultores is a boutique consulting firm delivering customized technology solutions to clients across Latin America, North America, and Europe. The firm provides end-to-end support across the SAP lifecycle, including implementation, upgrades, and ongoing management, to clients in the retail, manufacturing, finance, logistics, energy, healthcare, and automotive industries. Alamo Consultores’ service offerings span functional and technical consulting, system migrations, sustainability consulting, digital transformation, and outsourcing. “At Alamo Consultores, we focus on turning complexity into clarity, enabling clients to evolve through technology with flexibility, integrity, and long-term vision,” said Pablo Villamil, founder and CEO. “Becoming a collaborating firm of Andersen Consulting allows us to expand our reac
INSERTING and REPLACING SBC Medical Group Holdings Announces Second Quarter 2025 Financial Results13.8.2025 16:15:00 EEST | Press release
Insert after the second paragraph, 9th bullet: First Half 2025 Highlights. The updated release reads: SBC MEDICAL GROUP HOLDINGS ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical” or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for the second quarter of fiscal year 2025 (three months ended June 30, 2025) and for the first half of fiscal year 2025 (six months ended June 30, 2025). Second Quarter 2025 Highlights Total revenues were $43 million, representing an 18% year-over-year decrease. Income from operations was $15 million, representing a 47% year-over-year decrease. Net Income attributable to SBC Medical Group was $2.5 million, representing an 87% year-over-year decrease. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shar
Amazfit Partners With Female Elite Trail Runners Ruth Croft and Rosa Lara Feliu to Drive Innovation in Sports Watches13.8.2025 16:00:00 EEST | Press release
Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), today announced a landmark partnership with Ruth Croft, one of the most accomplished trail and ultra runners in the world. The brand also welcomes Rosa Lara Feliu, a fast-rising Spanish mountain runner, to its growing global performance team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250813966185/en/ Amazfit Partners with female Elite Trail Runners Ruth Croft and Rosa Lara Feliu to Drive Innovation in Sports Watches Croft, born and raised in New Zealand, has spent more than a decade at the pinnacle of the sport. Her career includes prestigious wins at the Golden Trail World Series, Mont Blanc Marathon, OCC by UTMB, and Les Templiers, as well as top finishes at the sport’s most competitive ultras. Since stepping up to the ultra distance in 2020, she has claimed victories at Western States Endurance Run 100 miles, Tarawera 100K, and CCC by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom